

hernia occurred at the peritoneal flap closure site, and in the other case the hernia occurred at the peritoneal flap donor site.

CONCLUSIONS: Intra-abdominal complications following robot assisted peritoneal flap vaginoplasty require prompt surgical attention. In addition to hematoma and abscess, small bowel incarceration and internal hernias are important complications for the surgeon performing peritoneal flap vaginoplasty to consider.

Table 1. Patient demographics, preoperative exam, and intraoperative details.

Patient	Age (years) ^a	BMI (kg/m ²) ^a	Medical history	Stretched penile length (cm)	Operative time (min)	FTSG used	Intraoperative complications	Length of stay (days) ^a
1	34	20.6	None	12.5	169	Yes	None	5
2	22	18.3	Asthma	9.0	251	Yes	None	5
3	33	24.2	None	9.0	139	Yes	None	5
4	24	19.4	Depression, anorexia	7.0	202	Yes	None	5
5	22	24.2	None	9.0	185	Yes	None	5
6	21	16.6	Smoking, spontaneous pneumothorax	10.0	132	Yes	None	5

BMI, body mass index; FTSG, full-thickness skin graft
^aAt time of index surgery

Table 2. Postoperative complications, management, and long-term outcomes.

Patient	Postoperative Complication ^a	Complication Management	Follow Up (days)	Vaginal Dilatation	Vaginal Intercourse?	Neocervical Orgasms?	Difficulty Urinating?
1	POD3 Intra-abdominal hematoma	Diagnostic laparoscopy, hematoma evacuation	188	15.2cm deep with 3.8cm dilator	No	No	No
2	POD41 Intra-abdominal abscess	Diagnostic laparoscopy, abscess aspiration	608	15.2cm deep with 3.8cm dilator	Yes	Yes	Yes—urinary spray
3	POD131, POD 172 Recurrent intra-abdominal abscess	Diagnostic laparoscopy, abscess aspiration (DSH)	370	3.8cm deep with 2.9cm dilator	No	Yes	No
		Diagnostic laparoscopy, lysis of adhesions, transneovaginal abscess drainage, colectomy					
4	POD25, POD33, POD96, POD170, POD235 Recurrent SBOs	Bowel rest	635	15.2cm deep with 3.8cm dilator	No	Yes	No
5	POD7 Internal hernia with SBO	Diagnostic laparoscopy, internal hernia reduction	370	15.2cm deep with 3.8cm dilator	No	Yes	No
6	POD417 Internal hernia with SBO	Diagnostic laparoscopy, internal hernia reduction	433	15.2cm deep with 3.8cm dilator	Yes	Yes	No

POD, postoperative day; DSH, outside hospital; SBO, small bowel obstruction
^aPost-operative day refers to number of days from the index operation that the return to the operating room occurred. In patients who did not require return to the operating room, post-operative day refers to days from index operation that readmission to the hospital occurred.

Source of Funding: N/A

PD29-12
IS A BMI CUTOFF FOR GENDER AFFIRMATION SURGERY SCIENTIFICALLY SUPPORTED?

Erin Carter*, Salt Lake City, UT; Michael Safir, San Francisco, CA; Ashley DeLeon, Curtis Crane, Richard Santucci, Austin, TX

INTRODUCTION AND OBJECTIVE: Gender-affirming surgeries (GAS) are increasingly in demand. Though these procedures are elective, there is a significant morbidity and mortality benefit. Access to GAS is an ongoing discussion and must balance operative risks, individual risk factors, and potential benefit. Many of those offering these procedures list an ideal or inflexible upper limit of body mass index (BMI). The objective of this work is to determine if there is a relationship between BMI and surgical outcomes for GAS, both chest and genital, both masculinizing and feminizing. Additionally, we seek to evaluate whether any such relationship between BMI and outcomes suggests that a cutoff should (or should not) be considered for access to GAS.

METHODS: The scientific literature was searched for original articles reporting on any GAS, including chest, genital, masculinizing, and feminizing procedures. Review articles and abstracts were excluded. We extracted BMI cutoff criteria, reported BMI of each cohort, and statistically evaluated outcomes from each article. A similar search was performed for selected analogous soft-tissue surgeries for comparison.

RESULTS: The highest and lowest BMI reported were 54 and 14.6, both for masculinizing chest surgery. 6 groups reported using BMI upper limits of 25-33 or morbid obesity to undergo GAS. 3 recommended or required an alternative surgical approach for BMI greater than 27-30. 2 specified that BMI is not considered a contraindication for GAS at their institution(s). Of those that reported BMI, 77% (n=34/44) did not specify using BMI to qualify for GAS. It was common for reported BMI mean, standard deviation, and/or ranges to suggest that GAS may have been discouraged or considered contraindicated in obese patients (e.g. 24.8 ± 1.84), though this is of limited credibility without known ranges. 48% (n=21/44) evaluated surgical outcomes in relation to BMI. 11 individual criteria were found to be statistically significant; most commonly choice of surgical approach (n=7/11, 64%).

CONCLUSIONS: In a comprehensive review of the literature, we found limited evidence that suggests high BMI is associated with higher risk of complications. The available data supports using high BMI as a proxy for more dangerous health conditions (i.e. diabetes, hypertension, cardiac disease) which must be optimized preoperatively for safety, as in any patient. A higher risk of uncommon or non-life threatening complications may not justify BMI limits to GAS, as long as patient and surgeon acknowledge the higher risk of common obesity related complications, as in other elective but indicated surgeries.

Source of Funding: None